SNP Genetic Testing for Canine Peripheral Neuropathy Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for peripheral neuropathies, such as Charcot-Marie-Tooth disease and acquired peripheral neuropathy in dogs, are symptomatic and do not modify or reverse the disease progression, largely due to a lack of understanding of the genetic basis and the absence of suitable large animal models.
Innovation Solution
A genome-wide association study using Labrador Retrievers identifies a single nucleotide polymorphism (SNP) on CFA1 associated with acquired peripheral neuropathy, which tags the causal variant and is inherited in an autosomal dominant fashion, enabling genetic testing for selective breeding and clinical management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic treatments are used for peripheral neuropathy, then symptom management is achieved, but disease progression cannot be modified or reversed
Solution Approach 1:
The patent performs preliminary genetic testing to identify carriers of the I257N mutation in the COL4A1 gene before clinical signs of peripheral neuropathy develop. This allows for early identification and potential intervention, transforming the approach from reactive symptom management to proactive disease modification by selecting against affected individuals in breeding programs.
2Productivity
If genetic testing is implemented for selective breeding, then disease prevalence can be reduced, but complexity of diagnostic procedures increases
Solution Approach 1:
The patent extracts the specific diagnostic information needed (presence of the I257N mutation in COL4A1) from the complex genome, focusing only on the single causative mutation rather than analyzing the entire genome. This extraction approach simplifies the testing system while maintaining high accuracy for detecting peripheral neuropathy susceptibility in Labrador Retrievers.
3Reliability
If large animal models are developed for peripheral neuropathy research, then understanding of disease mechanism improves, but time and resources required increase
Solution Approach 1:
The patent uses Labrador Retrievers with the I257N mutation as a natural copy or model of human peripheral neuropathy conditions. By studying this genetically defined canine population, researchers can investigate disease mechanisms and test interventions in a large animal model that naturally replicates human-like peripheral neuropathy, avoiding the need to create artificial models from scratch.
Data Source
AI summary
Methods and kits for diagnosing propensity to exhibit acquired peripheral neuropathy in dogs are described. The methods and kits test dogs for presence of a single-nucleotide polymorphism (SNP) TIGRP2P18586_rs8746233. Presence of the SNP indicates an increased likelihood of the dog exhibiting an acquired peripheral neuropathy. This information can be used to guide preemptive clinical treatment of the animal for peripheral neuropathy and to choose dogs for selective breeding programs.